Evidence map›Paper›PMID 36141802›Full record

ArticleInternational journal of environmental research and public health2022

Two-Dose Vaccination Significantly Prolongs the Duration from Symptom Onset to Death: A Retrospective Study Based on 173,894 SARS-CoV-2 Cases in Khyber Pakhtunkhwa, Pakistan.

Qianqian Song, Naseem Asghar, Ata Ullah, Baosheng Liang, Mengping Long, Taobo Hu, Xiaohua Zhou

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qianqian SongDepartment of Biostatistics, Peking University, Beijing 100191, China.ORCID 0000-0003-1511-488X
Naseem AsgharDepartment of Statistics, Abdul Wali Khan University, Mardan 23200, Pakistan.
Ata UllahDivision of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China.
Baosheng LiangDepartment of Biostatistics, Peking University, Beijing 100191, China.ORCID 0000-0003-3500-0820
Mengping LongDepartment of Pathology, Peking University Cancer Hospital, Beijing 100083, China.
Taobo HuChongqing Research Institute of Big Data, Peking University, Chongqing 401121, China.ORCID 0000-0001-5124-7167
Xiaohua ZhouDepartment of Biostatistics, Peking University, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This research was carried out to quantify the duration from symptom onset to recovery/death (SOR/SOD) during the first four waves and the Alpha/Delta period of the epidemic in Khyber Pakhtunkhwa, Pakistan, and identify the associated factors. A total of 173,894 COVID-19 cases were admitted between 16 March 2020 and 30 November 2021, including 458 intensive care unit (ICU) cases. The results showed that the case fatality rate (CFR) increased with age, and females had a higher CFR. The median SOR of ICU cases was longer than that of non-ICU cases (27.6 vs. 17.0 days), while the median SOD was much shorter (6.9 vs. 8.4 days). The SOR and SOD in the Delta period were slightly shortened than the Alpha period. Age, cardiovascular diseases, chronic lung disease, diabetes, fever, breathing issues, and ICU admission were risk factors that were significantly associated with SOD (

Indexed as

COVID-19SARS-CoV-2FemaleHumansPakistanRetrospective StudiesSuperoxide DismutaseVaccinationSuperoxide Dismutasecase fatality rateCOVID-19symptom onset to deathsymptom onset to recoveryvaccine dose

Identifiers

PMID36141802
PMCPMC9517462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.